Clicky

Palisade Bio, Inc.(PALI) News

Date Title
Sep 25 Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
Jul 31 Palisade Bio Participates in Virtual Investor “What this Means” Segment
Jul 29 Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
Jun 24 Palisade Bio to Participate in the Virtual Investor Closing Bell Series
Jun 21 Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
May 7 Palisade Bio Appoints Margery Fischbein to its Board of Directors
May 7 Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Apr 3 Palisade Bio Announces 1-for-15 Reverse Stock Split
Jan 9 Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
Dec 28 Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108